Literature DB >> 27987250

Lung disease severity in idiopathic pulmonary fibrosis is more strongly associated with impedance measures of bolus reflux than pH parameters of acid reflux alone.

S Gavini1,2, L F Borges1,2, R T Finn2,3, W-K Lo1,2, H J Goldberg2,4, R Burakoff1,2, N Feldman1, W W Chan1,2.   

Abstract

BACKGROUND: Gastroesophageal reflux (GER) has been associated with idiopathic pulmonary fibrosis (IPF). Pathogenesis may be related to chronic micro-aspiration. We aimed to assess objective measures of GER on multichannel intraluminal impedance and pH study (MII-pH) and their relationship with pulmonary function testing (PFT) results, and to compare the performance of pH/acid reflux parameters vs corresponding MII/bolus parameters in predicting pulmonary dysfunction in IPF.
METHODS: This was a retrospective cohort study of IPF patients undergoing prelung transplant evaluation with MII-pH off acid suppression, and having received PFT within 3 months. Patients with prior fundoplication were excluded. Severe pulmonary dysfunction was defined using diffusion capacity of the lung for carbon monoxide (DLCO) ≤40%. Six pH/acid reflux parameters with corresponding MII/bolus reflux measures were specified a priori. Multivariate analyses were applied using forward stepwise logistic regression. Predictive value of each parameter for severe pulmonary dysfunction was calculated by area-under-the-receiver-operating-characteristic-curve or c-statistic. KEY
RESULTS: Forty-five subjects (67% M, age 59, 15 mild-moderate vs 30 severe) met criteria for inclusion. Patient demographics and clinical characteristics were similar between pulmonary dysfunction groups. Abnormal total reflux episodes and prolonged bolus clearance time were significantly associated with pulmonary dysfunction severity on univariate and multivariate analyses. No pH parameters were significant. The c-statistic of each pH parameter was lower than its MII counterpart in predicting pulmonary dysfunction. CONCLUSIONS & INFERENCES: MII/bolus reflux, but not pH/acid reflux, was associated with pulmonary dysfunction in prelung transplant patients with IPF. MII-pH may be more valuable than pH testing alone in characterizing GER in IPF.
© 2016 John Wiley & Sons Ltd.

Entities:  

Keywords:  gastroesophageal reflux; idiopathic pulmonary fibrosis; lung transplant; multichannel intraluminal pH-impedance study; pH/impedance study

Mesh:

Year:  2016        PMID: 27987250     DOI: 10.1111/nmo.13001

Source DB:  PubMed          Journal:  Neurogastroenterol Motil        ISSN: 1350-1925            Impact factor:   3.598


  6 in total

Review 1.  Gastroesophageal Reflux and Idiopathic Pulmonary Fibrosis.

Authors:  Marco E Allaix; Fabrizio Rebecchi; Mario Morino; Francisco Schlottmann; Marco G Patti
Journal:  World J Surg       Date:  2017-07       Impact factor: 3.352

2.  Mycophenolate therapy in interstitial pneumonia with autoimmune features: a cohort study.

Authors:  Sara S McCoy; Zubin Mukadam; Keith C Meyer; Jeffrey P Kanne; Cristopher A Meyer; Maria D Martin; Emmanuel Sampene; Scott W Aesif; Laurie N Rice; Christie M Bartels
Journal:  Ther Clin Risk Manag       Date:  2018-11-01       Impact factor: 2.423

3.  Idiopathic pulmonary fibrosis and GERD: links and risks.

Authors:  Matteo Ghisa; Carla Marinelli; Vincenzo Savarino; Edoardo Savarino
Journal:  Ther Clin Risk Manag       Date:  2019-09-05       Impact factor: 2.423

Review 4.  Comorbidity in idiopathic pulmonary fibrosis - what can biomarkers tell us?

Authors:  Tiago M Alfaro; Carlos Robalo Cordeiro
Journal:  Ther Adv Respir Dis       Date:  2020 Jan-Dec       Impact factor: 4.031

Review 5.  Cough in Idiopathic Pulmonary Fibrosis.

Authors:  Jennifer Mann; Nicole S L Goh; Anne E Holland; Yet Hong Khor
Journal:  Front Rehabil Sci       Date:  2021-10-18

6.  Abnormal Bolus Reflux Is Associated With Poor Pulmonary Outcome in Patients With Idiopathic Pulmonary Fibrosis.

Authors:  Lawrence F Borges; Vikrant Jagadeesan; Hilary Goldberg; Sravanya Gavini; Wai-Kit Lo; Robert Burakoff; Natan Feldman; Walter W Chan
Journal:  J Neurogastroenterol Motil       Date:  2018-07-30       Impact factor: 4.924

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.